Clinical Trial Update: Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study [Phase 2]

View source ↗

Summary

Phase II trial of Nolvadex with or without Iressa for metastatic ER+/PgR+ breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Iressa (gefitinib)
• Nolvadex (tamoxifen)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED